GlycoMimetics Inc represents a strong commitment to scientific innovation and improving patient outcomes. The company's core values include integrity, collaboration, and scientific excellence. With a focus on developing novel glycomimetic therapeutics, GlycoMimetics strives to address unmet medical needs in areas such as oncology and hematology. By leveraging their expertise in carbohydrate chemistry, GlycoMimetics aims to deliver breakthrough treatments that have the potential to positively impact patients' lives. Through a culture of innovation and a dedication to integrity, GlycoMimetics is driven by a corporate philosophy centered on advancing science and enriching the healthcare landscape.

GlycoMimetics Inc is primarily present in the United States.

GlycoMimetics Inc has achieved several significant milestones. The company successfully developed and advanced multiple product candidates, including their lead candidate, rivipansel, which is being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease. GlycoMimetics Inc also entered into a collaboration with Pfizer Inc, a global pharmaceutical company, to develop and commercialize rivipansel. Additionally, the company successfully completed a Phase 3 clinical trial for rivipansel, demonstrating its potential efficacy and safety. These achievements highlight GlycoMimetics Inc's dedication to developing innovative therapies and forging valuable partnerships in the pharmaceutical industry.

GlycoMimetics Inc is a pharmaceutical company specializing in the discovery and development of novel glycobiology-based therapies. Founded in 2003, GlycoMimetics focuses on developing drugs that inhibit selectin molecules to treat diseases such as sickle cell disease, acute myeloid leukemia, and other inflammatory conditions. The company's proprietary drug candidates have shown promising results in clinical trials, demonstrating their potential to address unmet medical needs. With a strong commitment to innovation and scientific excellence, GlycoMimetics continues to advance its pipeline and collaborate with industry leaders to bring transformative treatments to patients worldwide.

The main competitors of GlycoMimetics Inc in the market include companies such as Pfizer, Inc., Eli Lilly and Company, and Novartis AG.

GlycoMimetics Inc is primarily active in the biotechnology industry.

The business model of GlycoMimetics Inc focuses on the development and commercialization of therapeutics for patients with unmet medical needs. The company is dedicated to creating innovative, targeted therapies that address specific diseases and conditions. GlycoMimetics Inc leverages its expertise in glycobiology to design and develop novel small molecules that mimic the natural biological processes in the body. By targeting glycans, essential components of cellular interactions, the company aims to develop breakthrough treatments for various diseases, including hematologic malignancies and sickle cell disease. With a focus on research and strategic partnerships, GlycoMimetics Inc strives to bring transformative therapies to patients worldwide.

GlycoMimetics KGV ir -0,28.

GlycoMimetics KUV ir 0.

AlleAktien kvalitātes vērtējums GlycoMimetics ir 3/10.

Pašreiz nevar aprēķināt apgrozījumu GlycoMimetics.

gaidāmā GlycoMimetics peļņa ir -39,78 milj. USD.

GlycoMimetics Inc is a biotechnology company based in the USA. The company's business model is based on the development and commercialization of novel therapeutic agents that are based on the imitation of carbohydrate structures in cells and tissues. These substances, called GlycoMimetics, can be used to treat a variety of diseases, particularly those related to disorders of the circulatory system, inflammatory processes, or cancer growth. The company is divided into two main areas: research and development (R&D) and production and marketing (Sales & Marketing), with activities focusing on both internal and external collaboration. In the R&D area, intensive research is being conducted to identify new GlycoMimetics, with the company working closely with academic institutions and other biotechnology companies to maximize the full potential of its research results. A focus of GlycoMimetics Inc is the research and development of drugs for the treatment of cancer. Novel Glycomimetics are being targeted as targets for the development of cancer therapeutics. The company's current developments focus on drug candidates for the therapy of acute myeloid leukemia (AML), non-Hodgkin lymphoma, and colon cancer. In addition, new treatment approaches to improve blood formation and blood clotting are also being developed. These approaches have the potential to reduce the need for blood transfusions or improve the tolerability of other medications. Another future business field of GlycoMimetics Inc is the targeted addressing of inflammatory processes. GlycoMimetics have the ability to selectively target inflammatory cells and leave healthy cells unaffected without side effects or damage. This is used in the development of treatment options for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis (MS), psoriasis, and autoimmune diseases such as type I diabetes. GlycoMimetics Inc offers its products directly to medical institutions as well as in cooperation with leading pharmaceutical companies. International partnerships are already being formed to globally market the effectiveness of GlycoMimetics on the world market. As a result, GlycoMimetics secures numerous partnerships to profitably sell its expertise and developments. Overall, the business model of GlycoMimetics Inc is focused on the identification and commercialization of innovative and effective GlycoMimetics. The application spectrum and potential of GlycoMimetics are wide-ranging, supporting the company's growth and expansion strategy. GlycoMimetics will revolutionize the treatment of numerous patients and usher in a new era in medicine.

GlycoMimetics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt GlycoMimetics vai uzņēmums nedod dividendes.

GlycoMimetics ISIN ir US38000Q1022.

GlycoMimetics WKN ir A1W8HZ.

GlycoMimetics simbols ir GLYC.

Pēdējo 12 mēnešu laikā GlycoMimetics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos GlycoMimetics plāno maksāt dividendes 0 USD apmērā.

GlycoMimetics pašreizējā dividendu rentabilitāte ir .

GlycoMimetics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

GlycoMimetics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

GlycoMimetics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu GlycoMimetics apmērā 0 USD, kas tika izmaksāta 21.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 21.08.2024..

Pēdējās dividendes izmaksa notika 21.08.2024..

Gadā 2023, GlycoMimetics izmaksāja 0 USD dividendes.

GlycoMimetics dividendes tiek izmaksātas USD.